RBP4 and atrophic macular degeneration: Although the overall cohort showed no statistically significant retardation of the growth rate of geographic atrophy due to an insufficient number of participants achieving a serum RBP4 level less than 1 μM, a further clinical trial targeting RBP4 is ongoing (clinicaltrials.gov identifier: NCT03735810).